Repositioning Candidate Details

Candidate ID: R0800
Source ID: DB05444
Source Type: investigational
Compound Type: small molecule
Compound Name: Iroxanadine
Synonyms: Iroxanadine
Molecular Formula: C14H20N4O
SMILES: C(C1CONC(=N1)C1=CN=CC=C1)N1CCCCC1
Structure:
DrugBank Description: BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease). BRX-235 also causes translocation of calcium-dependent protein kinase C isoform to membranes.
CAS Number: 276690-58-5
Molecular Weight: 260.3348
DrugBank Indication: Investigated for use/treatment in atherosclerosis and vascular diseases as a cardioprotective agent. Its use has also been suggested for the prevention of early restenosis following vascular surgery or balloon angioplasty.
DrugBank Pharmacology: EC (endothelial cell) function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease). BRX-235 induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis.
DrugBank MoA: BRX-235 induces phosphorylation of p38 SAPK, which plays an important role in EC (endothelial cell) homeostasis.
Targets: --
Inclusion Criteria: Indication associated